Study of INCB123667 in Subjects With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05238922. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).
Study identification
- NCT ID
- NCT05238922
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 291 participants
Conditions and interventions
Conditions
Interventions
- INCB0123667 Drug
- Palbociclib Drug
- Bevacizumab Drug
- Olaparib Drug
- Paclitaxel Drug
- Ribociclib Drug
- Fulvestrant Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2022 (Actual)
- Primary completion
- Jul 27, 2027 (Estimated)
- Completion
- Aug 31, 2027 (Estimated)
- Last update posted
- Jul 21, 2026
2022 – 2027
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | — |
| City of Hope-Lennar Foundation Cancer Center | Irvine | California | 92618 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | — |
| Rocky Mountain Cancer Centers-Sky Ridge | Lone Tree | Colorado | 80124 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Mount Sinai Medical Center Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10022 | — |
| New York Presbyterian/Weill Cornell | New York | New York | 10065 | — |
| Ny Cancer and Blood Specialists | Shirley | New York | 11967 | — |
| Carolina Bio-Oncology Institute, Pllc | Huntersville | North Carolina | 28078 | — |
| University of Pennsylvania Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh Cancer Institute Cancer Services | Pittsburgh | Pennsylvania | 15213 | — |
| Allegheny Health Network | Pittsburgh | Pennsylvania | 15224 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Fort Worth South Henderson | Fort Worth | Texas | 76104 | — |
| Virginia Cancer Institute | Fairfax | Virginia | 22031 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05238922, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05238922 live on ClinicalTrials.gov.